Free Trial

Matinas BioPharma (MTNB) Stock Forecast & Price Target

Matinas BioPharma logo
$0.62
-1.31 (-67.88%)
(As of 10/31/2024 ET)

Matinas BioPharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
0

Based on 1 Wall Street analysts who have issued ratings for Matinas BioPharma in the last 12 months, the stock has a consensus rating of "Hold." Out of the 1 analysts, 1 has given a hold rating for MTNB.

Consensus Price Target

N/A

Get the Latest News and Ratings for MTNB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Matinas BioPharma and its competitors.

Sign Up

MTNB Analyst Ratings Over Time

TypeCurrent Forecast
11/1/23 to 10/31/24
1 Month Ago
10/2/23 to 10/1/24
3 Months Ago
8/3/23 to 8/2/24
1 Year Ago
11/1/22 to 11/1/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/A$3.00$3.00$3.00
Forecasted UpsideN/A1,515.51% Upside1,515.51% Upside733.33% Upside
Consensus Rating
Hold
Buy
Buy
Buy

MTNB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MTNB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Matinas BioPharma Stock vs. The Competition

TypeMatinas BioPharmaMedical CompaniesS&P 500
Consensus Rating Score
NaN
2.79
2.50
Consensus RatingN/AModerate BuyHold
Predicted UpsideN/A16,513.33% Upside10.27% Upside
News Sentiment Rating
Negative News

See Recent MTNB News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/31/2024Maxim Group
4 of 5 stars
 Reiterated RatingBuy ➝ Hold
10/11/2023BTIG Research
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$3.00+368.01%
1/31/2023HC Wainwright
2 of 5 stars
 Reiterated RatingBuy$3.00+420.37%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:09 PM ET.


MTNB Forecast - Frequently Asked Questions

According to analysts, Matinas BioPharma's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Matinas BioPharma has been rated by research analysts at Maxim Group in the past 90 days.

Analysts like Matinas BioPharma less than other "medical" companies. The consensus rating for Matinas BioPharma is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MTNB compares to other companies.


This page (NYSEAMERICAN:MTNB) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners